Frontotemporal dementia and mitochondrial DNA transitions by Grazina, M et al.
www.elsevier.com/locate/ynbdi
Neurobiology of Disease 15 (2004) 306–311Frontotemporal dementia and mitochondrial DNA transitions
Manuela Grazina,a,b Filipe Silva,b,c Isabel Santana,c Beatriz Santiago,c Caˆndida Mendes,b
Marta Simo˜es,b Miguel Oliveira,b Luı´s Cunha,c and Catarina Oliveiraa,b,c,*
aBiochemistry Institute, Faculty of Medicine, University of Coimbra, 3004-504, Coimbra, Portugal
bNeurochemistry Department, Center for Neurosciences of Coimbra, University of Coimbra, 3004-517, Coimbra, Portugal
cNeurology Unit, University Hospital of Coimbra, 3000-075, Coimbra, PortugalReceived 16 May 2003; revised 3 November 2003; accepted 5 November 2003Frontotemporal dementia (FTD) is the second most common type of
primary degenerative dementia. Some patients present an overlap
between Alzheimer’s disease (AD) and FTD both in neuropathological
and clinical aspects. This may suggest a similar overlap in physiopa-
thology, namely an involvement of mitochondrial DNA (mtDNA) in
FTD, as it has been associated to AD. To determine if mtDNA is
involved in FTD, we performed a Polymerase Chain Reaction–
Restriction Fragment Length Polymorphism (PCR–RFLP) analysis,
specific to mtDNA NADH Dehydrogenase subunit 1 (ND1) nucleotides
3337–3340, searching for mutations previously described in Parkin-
son’s and AD patients. We could identify one FTD patient with two
mtDNA transitions: one already known (3316 G-to-A) and another
unreported (3337 G-to-A). Additionally, mitochondrial respiratory
chain complex I activity was reduced in leukocytes of this patient (36%
of the control mean activity). To our knowledge, this is the first report
of mtDNA variants in FTD patients.
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Frontotemporal dementia (FTD) is the second most common
type of primary degenerative dementia (Andreasen et al., 1999;
Brun, 1993). FTD is the generic designation of a group of
disorders, which includes Frontal Lobe Dementia, Pick Disease
and Motor Neuron Disease (Brun et al., 1994), as well as inherited
neurodegenerative diseases that have been linked to chromosome
17, termed FTDP-17 (Lee et al., 2001). Although these dementias
have been difficult to characterise due to their clinical variability,
the most common feature is a predominant frontal lobe syndrome
(Sjo¨gren et al., 1997), which sometimes can also be observed in
more severe cases of Alzheimer’s disease (AD) and in Vascular0969-9961/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
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symptoms, mild memory impairment and preservation of spatial
orientation are the most remarkable differences between FTD and
AD (Barber et al., 1995). Parkinsonian symptoms and motor
neuron dysfunction may be observed in special forms of FTD
and are useful in the differentiation between the two conditions
(Foster et al., 1997). Because it often affects people or families in
midlife, FTD is also frequently confused with primary psychiatric
disorders (McKhann et al., 2001; Stevens et al., 1998).
Neuropathology in FTD is characterised by loss of neurons,
neuropil vacuolation and gliosis in the superficial cortical layers of
the frontal and anterior temporal lobes (Brun, 1993), basal ganglia
and substantia nigra (Rizzu et al., 1999), and by the presence of
pathological tau proteins (Vermersch et al., 1995), which are also
observed in the brain of AD patients (Foster et al., 1997; Sjo¨gren et
al., 2000; Spillantini et al., 1998). Tau protein is a phosphoprotein
associated with microtubules and responsible for its assembly and
stabilization (Goedert et al., 1991). Self-association of hyperphos-
phorylated and insoluble form of tau protein in straight and twisted
filaments creates argyrophilic or T-positive neuropil inclusions
with or without the characteristics of pick bodies or ballooned
neurons, as well as argyrophilic or T-positive glial inclusions
(Spillantini et al., 1998). The biochemical analyses of tau protein
abnormalities have proven to be useful in the classification of FTD
(Dickson, 1997).
By linkage analysis, FTDP-17 was localized at chromosome
17q21–q23 (Lynch et al., 1994) and Wilhelmsen et al. (1994)
mapped the disinhibition–dementia–parkinsonism–amyotrophy
complex locus to 17q21–q22. The first missense and splice site
mutations in a family pedigree with FTDP-17 were found in the tau
gene (Hutton et al., 1998), and several mutations have been
described ever since in this gene among the different families with
cases diagnosed as FTDP-17 (Bue´e and Delacourte, 2001). How-
ever, only 10–15% of cases of FTD exhibit mutations in the Tau
gene (Wilhelmsen et al., 2001). Raux et al. (2000) found a
previously unreported heterozygous CTA-to-CCA mutation at
codon 113 of the Presenilin 1 (PS1) gene, and this finding implies
that the presence of PS1 mutations must be considered in FTD
pedigrees with no detectable Tau gene mutation. Recently, Gyde-
sen et al. (2002) have identified and studied a large kindred with
FTD inherited as an autosomal dominant trait, which was mapped
to the pericentromeric region of chromosome 3, suggesting that
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FTD. Also, a Swiss FTD kindred showed several recombination
events for chromosomes 3 and 17, but patients shared a haplotype
on chromosome 9q21–22, indicating that Tau is not at the origin of
FTD in this family (Savioz et al., 2003).
Chang et al. (1995) reported a patient with FTD and motor
neuron disease with neuronal ultrastructural abnormalities and
hypothesized that a mitochondrial dysfunction or defective trans-
port of mitochondria into axonal processes could be a potential
cause for the co-association.
Due to the neuropathological and clinical overlapping of AD
and FTD, mitochondrial DNA (mtDNA) may be a causal factor for
both diseases. According to several reports, we have recently
reported mtDNA mutations in two AD patients (unpublished
results). To analyse the possibility of the mtDNA NADH Dehy-
drogenase subunit 1 (ND1) gene being involved in FTD, we have
studied 3 FTD patients and 21 healthy age-matched control
subjects mtDNA ND1 gene nucleotides 3337–3340 using Poly-
merase Chain Reaction–Restriction Fragment Length Polymor-
phism (PCR–RFLP) analysis.Fig. 1. Photograph under ultraviolet light of agarose gel stained with
ethidium bromide showing mitochondrial DNA (mtDNA) fragments from
restriction enzyme analysis of the PCR product of primers PR5 and PR3
using Csp 6I. (Lane 1) PCR product not digested; (Lane 2) PCR negative
control; (Lane 3) U0 cell DNA sample; (Lane 4) pUC19 DNA/Msp I (Hpa
II) Marker 23, ready-to-use (MBI Fermentas); (Lane 5) FTD patient DNA
sample; (Lane 6) healthy age-matched control DNA sample.Materials and methods
We have studied three patients, one female (patient 1) and two
male (patients 2 and 3), with diagnosis of FTD (age range: 54–67
years, mean: 58.33 F 7.51 years), as defined by standard criteria
(Brun et al., 1994; McKhann et al., 2001), followed at the
Neurological Unit of the University Hospital of Coimbra. Global
cognitive impairment was quantified using the Mini-Mental State
Examination (MMSE) (Folstein et al., 1975) and global dementia
severity was staged as mild, moderate and severe. Twenty-one
healthy age-matched control subjects free of progressive neurolog-
ical disorders, 14 female and 7 male (age range: 54–67 years;
mean: 60.19 F 4.57 years), were randomly recruited at the
Neurological Unit of the University Hospital of Coimbra, sharing
similar socioeconomic status as the FTD patients. All the individ-
uals mentioned in this study gave informed consent for the
analyses performed.
We have extracted total cellular DNA (nuclear plus mitochon-
drial) from peripheral leukocytes, isolated from blood after
erythrocytes lysis, using a standard phenol-chloroform method.
Polymerase Chain Reaction (PCR) was performed in a TGradient
thermocycler (Biometra) to obtain a 289-base pair (bp) fragment.
The amplification conditions were 30 cycles at 95jC for 30 s,
57jC for 30 s and 72jC for 30 s, using a master mix containing
0.25–0.5 Ag of total cellular DNA, 200 AM each dNTP (Amer-
sham Biosciences), 1 unit of Taq Polymerase (Amersham Bio-
sciences), 1 Taq Polymerase Buffer (Amersham Biosciences)
and 1 AM of each primer PR5 (5V-AAAGGACAAGAGAAA-
TAAGGCC-3V) and PR3 (5V-GGGCCTTTGCGTAGTTGTCT-3V,
specially designed with one mismatch for mutation specific
(MS)-PCR for detection of wild-type mtDNA sequence at nucle-
otide 3397) in a final reaction volume of 25 Al. This procedure
was followed by Restriction Fragment Length Polymorphism
(RFLP) analysis with endonuclease Csp 6I (MBI-Fermentas),
according to the manufacturer’s instructions, which produces
two fragments (79 and 210 bp) if the sequence is wild-type and
only one if there is a mutation at any of the nucleotides 3337–
3340. All the DNA samples were analysed randomly in a blinding
way. Additionally, we used the same conditions to amplify 250 ngof a DNA sample extracted from U0 cells which are devoided of
mtDNA (Parfait et al., 1998). Finally, to confirm the presence of a
mutation, we have performed sequence analysis of purified frag-
ments with GFXk PCR DNA and Gel Band Purification Kit
(Amersham Biosciences) using CEQk DTCS-Quick Start Kit
(Beckman Coulter) according to the manufacturer’s instructions,
and the reactions were analysed by CEQk 2000XL DNA
Analysis System (Beckman Coulter) and compared to the Cam-
bridge-Sequence of the human mitochondrial genome (Anderson
et al., 1981).
Peripheral leukocytes were isolated from patient 1 and five
healthy control subjects using 50 ml of blood (in EDTA). The
activities of the respiratory chain complexes I (NADH-cytochrome
c oxidoreductase; EC 1.6.5.3), II (succinate dehydrogenase; EC
1.3.5.1), II + III (succinate-cytochrome c oxidoreductase; EC
1.10.2.2), IV (cytochrome c oxidase; EC1.9.3.1), V (ATP synthase;
EC 3.6.1.34) and citrate synthase (CS; EC 4.1.3.7) were evaluated
as described (Rustin et al., 1994). The results of the enzymatic
activities were expressed normalized to CS.Results
We have found one FTD patient (patient 1) with a homoplasmic
mtDNA mutation at nucleotides 3337–3340 by PCR–RFLP
analysis (Fig. 1). The affected subject was a 54-year-old woman
and the diagnosis of disease occurred at the age of 52 years. Her
mother had died at 63 years age with dementia. She presented early
personality change, with unconcern and inappropriate behaviour,
reduction in speech output and no spatial disorientation. The
investigation confirmed the probable diagnosis of FTD. The
electroencephalogram was normal; the computed tomography scan
showed frontal atrophy and the characteristic pattern of fronto-
temporal hypoperfusion on single-photon emission computed to-
mography was observed. Two years later she presented stereotyped
behaviour, speech was severely reduced and with echolalia and the
Fig. 2. Results of fluorescence-based automated sequencing analysis. (A) mtDNA sequence surrounding the nucleotide 3316A, marked with *. (B) mtDNA
sequence surrounding the nucleotide 3337A, marked with *.
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tia (MMSE 8).
The PCR–RFLP result was confirmed by sequence analysis.
This patient presented an unreported transition G-to-A at nucleo-
tide 3337 of the mtDNA ND1 gene, which promotes the change of
valine to methionine in the peptide chain (Fig. 2). Additionally,
this patient presented a known G-to-A transition at nucleotide
3316 of the mtDNA ND1 gene (Fig. 2), which promotes the
change of alanine to threonine in the peptide chain. This transition
was first described in non-insulin-dependent diabetes mellitus
(NIDDM) patients (Nakagawa et al., 1995) and was also described
in patients with adult and childhood insulin-dependent diabetes
mellitus, NIDDM and impaired glucose tolerance (Fukuda et al.,
1999; Ji et al., 2001; Matsuura et al., 1999; Nakano et al., 1998;
Odawara et al., 1996). This substitution was also reported in
patients with mitochondrial disorders (Matsumoto et al., 1999;Table 1
Mitochondrial respiratory chain enzymatic activities in leukocytes
I/CS II/CS II + III/CS IV/CS V/CS
Patient 1 0.0025a 0.16 0.31 1.27 0.41
Controls (n = 5)
Mean 0.0070 0.21 0.32 1.15 0.55
SD 0.0027 0.07 0.10 0.31 0.22
Minimum 0.0042 0.14 0.19 0.81 0.36
Maximum 0.0102 0.30 0.45 1.43 0.81
a This value is 36% of the control mean activity.Sternberg et al., 1998) and dilated cardiomyopathy (Arbustini et
al., 1998).
Another important fact is that no amplification of the U0 cell
DNA sample could be observed (Fig. 1). The three FTD patients
presented a q3/q3 genotype at APO E gene, studied according to
Crook et al. (1994).
The analysis of the mitochondrial respiratory chain enzymatic
activities revealed a deficiency of complex I (36% of the control
mean activity) in leukocytes of the patient carrying the mtDNA
transitions described (patient 1). Results are summarized in Table 1.Discussion
In a group of FTD patients and healthy age-matched control
subjects, we have identified two homoplasmic mtDNA variants in
one patient. The patient presented changes in nucleotides 3316
and 3337 of the mtDNA ND1 gene. The first alteration (3316 G-
to-A) promotes the change of a nonpolar alanine to a polar
threonine in an essentially hydrophobic peptide, a nucleotide
substitution that has been described in diabetes mellitus patients
(Fukuda et al., 1999; Matsuura et al., 1999; Nakano et al., 1998;
Odawara et al., 1996). However, the FTD patient in study does
not present any clinical evidence of diabetes mellitus. Evolutive
studies consider this alteration as weakly conserved among
hominoid primates (Anderson et al., 1981; Horai et al., 1995)
(Fig. 3) and was reported as a polymorphism related with
haplogroup A, present in the Asian populations (Herrnstadt et
Fig. 3. Evolutionary conservation among hominoid primates (Homo
sapiens (a), G. gorilla (b), Pan troglodytes (c), Pan paniscus (d) and P.
pygmaeus (e)). (A) 5VmtDNA sequence of NADH Dehydrogenase subunit 1
gene surrounding nucleotides 3316 and 3337 underline and bold. (B) N-
terminal amino acid sequence of NADH Dehydrogenase subunit 1 protein
with amino acid coded by nucleotides 3316 and 3337 underline and bold.
H. sapiens mtDNA sequence obtained from Anderson et al. (1981). G.
gorilla, P. troglodytes, P. paniscus and P. pygmaeus mtDNA sequences
were obtained from Horai et al. (1995).
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change of a valine to a methionine in the ND1 peptide, a
nucleotide substitution that is reported here for the first time, to
our knowledge. However, the absence of Rsa I cleavage site was
described before in several samples at nucleotide 3337 (Macaulay
et al., 1999). This may be due to a change at nucleotide 3337 but,
as Rsa I recognizes the same nucleotide sequence as Csp 6I, the
absence of cleavage may be due to a change in any of the four
nucleotides 3337, 3338, 3339 and 3340, because no sequencing
analysis was performed to confirm the PCR–RFLP results. The
nucleotide 3337 is quite conserved among hominoid primates.
However, in Pongo pygmaeus (orangutan), there is an A instead
of a G in the DNA sequence, corresponding to a methionine
instead of a valine in the ND1 peptide (Fig. 3). To our knowledge,
this is the first report of mitochondrial DNA variants in fronto-
temporal dementia patients.
It is quite remarkable that this patient presents two alterations in
the same region of the mtDNA ND1 gene, suggesting a possible
involvement of mitochondrial ND1 in the etiopathogenesis of FTD.
Such substitutions may have a functional meaning causing the
reduction of respiratory chain complex I activity and contributing
to the pathogenesis of the disorder. In fact, we could confirm a
reduction of 64% (compared to the control mean) of the complex I
activity in leukocytes of patient 1, reinforcing the possible involve-
ment of the mitochondrial respiratory chain in FTD. Moreover, it is
necessary to consider that those changes may be associated with
other mitochondrial or nuclear mutations and polymorphisms,
influencing the severity of FTD or even the onset of the disease.
The mtDNA mutations may have a cumulative effect, increasing
the probability to develop an energy failure. Recently, we have
reported three mtDNAvariants in two AD patients: one patient was
68 years old (65 years of age at onset of disease) with a change at
position 3199 of the 16S rRNA mtDNA gene and the other was 54years old (53 years of age at onset of disease) with two changes at
positions 3197 of the 16S rRNA mtDNA gene and 3338 of the
mtDNA ND1 gene (unpublished results). Taking this into account
and according to the results presented in this report, we may
hypothesize that mutations in the mtDNA region 3197–3338 may
decrease the age of onset of neurodegenerative disorders, probably
due to an impairment of the mitochondrial respiratory chain or
translation mechanisms. We are aware that additional studies are
needed to confirm or refuse this hypothesis.
It is also necessary to be cautious in dealing with mtDNA due
to its high mutation rate. In fact, mtDNA is a very susceptible
molecule, taking into account inefficient repair systems, absence of
protective histones, rare noncoding regions and its localization near
the electron transport chain. This is the main site of free radical
production, which may contribute to mtDNA oxidative damage
and additional injury, possibly involved in neurodegenerative
cascades, whenever a certain threshold is reached.
The fact that there was no amplification of the U0 cell DNA
sample indicates that no nuclear pseudogenes were amplified and
that we are studying the mtDNA genes of FTD patients and healthy
age-matched control subjects.
Interestingly, the three FTD patients presented a q3/q3 genotype
for the APO E gene. Although we cannot exclude that it may be a
coincidence favoured by the small number of samples studied, we
can hypothesize that a higher probability of developing FTD may
exist if q4 allele is absent of APO E genotype and a higher
probability of developing AD exists when q4 allele is present.
Certainly, further analysis may help to clarify this hypothesis.
Our results suggest that mutations in mtDNA ND1 nucleotides
3337–3340 do not account for a primary risk for developing FTD.
However, it is not excluded that other sequence regions of ND1 or
other mtDNA genes can be involved in the pathogenesis or onset
of FTD. In fact, our results indicate that mtDNA alterations in 16S
rRNA gene and ND1 gene may account for some risk in neurode-
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